Clinical Trial

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Study acronym: eVOLVE-Meso
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-10
notable Trial sites reduced: 178 -> 151 locations 2026-06-10
notable Primary completion pushed: 2027-11-19 -> 2028-11-16 2026-06-10
Trial Details
NCT Number NCT06097728
Lead Sponsor AstraZeneca
Conditions Unresectable Pleural Mesothelioma
Enrollment 863 participants
Start Date 2023-11-09
Primary Completion 2028-11-16 (estimated)
Study Completion 2028-11-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-28